» Articles » PMID: 12038777

New Aspects in Thrombosis Research: Possible Role of Mast Cells As Profibrinolytic and Antithrombotic Cells

Overview
Journal Thromb Haemost
Publisher Thieme
Date 2002 Jun 1
PMID 12038777
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Venous thromboembolism represents a significant cause of morbidity worldwide. The factors that underly thrombophilia are manifold. The concept of Virchow defines the well known triad of stasis, humoral factors, and pathologies of the vascular wall. In the current article, an additional factor, the "accumulation of repair cells" is discussed. This novel concept highlights the mast cell that accumulates around thrombosed vessels and provides a number of important repair molecules including heparin, profibrinolytic tPA, and fibrinogenolytic beta-tryptase. Thus, mast cell recruitment and activation may result in local thrombolysis and prevention of coagulation. In line with this concept, mast cell-deficient mice are more susceptible to lethal thrombogenic stimuli compared to normal mice. The factors (cytokines) that trigger mast cell accumulation and release of repair molecules have also been identified - the most important one appears to be stem cell factor (SCF). All in all. our novel concept suggests that the patho-physiology of thrombosis may involve a "physiologic" cell that provides the same repair molecules that are used for treatment of thrombotic disorders by the physician. Whether an altered availability of components of this cellular repair system can predispose for thrombophilia remains to be determined.

Citing Articles

Tyrosine Kinase Inhibitor-associated Cerebral Arterial Occlusive Disease Treated with High-flow Bypass Surgery: A Case Report.

Rai Y, Hara T NMC Case Rep J. 2023; 10:61-66.

PMID: 37065876 PMC: 10101701. DOI: 10.2176/jns-nmc.2022-0298.


Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis.

Seidel H, Hertfelder H, Oldenburg J, Kruppenbacher J, Afrin L, Molderings G Int J Mol Sci. 2021; 22(16).

PMID: 34445665 PMC: 8396658. DOI: 10.3390/ijms22168960.


Mast Cell Chymase and Kidney Disease.

Vibhushan S, Bratti M, Montero-Hernandez J, Ghoneimi A, Benhamou M, Charles N Int J Mol Sci. 2021; 22(1).

PMID: 33396702 PMC: 7795820. DOI: 10.3390/ijms22010302.


Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence.

van Haren F, Page C, Laffey J, Artigas A, Camprubi-Rimblas M, Nunes Q Crit Care. 2020; 24(1):454.

PMID: 32698853 PMC: 7374660. DOI: 10.1186/s13054-020-03148-2.


Spotlight on ponatinib in the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia: patient selection and perspectives.

Anagnostou T, Litzow M Blood Lymphat Cancer. 2019; 8:1-9.

PMID: 31360088 PMC: 6467344. DOI: 10.2147/BLCTT.S130197.